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Background: Several options have been proposed for the treatment of congenital
extrahepatic portosystemic shunts (cEHPSS) in dogs, but formal comparisons among
different treatment options are currently unavailable. A previous evidence-based
review (2012) found low quality of evidence for papers assessing the treatment of
cEHPSS in dogs.
Objectives: To assess the quality of evidence available in the treatment of cEHPSS,
summarize the current state of knowledge with respect to outcome after cEHPSS
management, and compare different treatment techniques.
Animals: Not used.
Methods: A bibliographic search was performed without date or language restric-
tions. Studies were assessed for quality of evidence (study design, study group sizes,
subject enrollment quality, and overall risk of bias) and outcome measures reported
(perioperative outcome, clinical outcome, and surgical or interventional outcome), all
reported with 95% confidence intervals. A network meta-analysis was performed.
Results: Forty-eight studies were included. Six retrospective studies (grade 4b) com-
pared 2 techniques and 7 were abstracts (grade 5). The quality of evidence was low
and risk of bias high. Regarding surgical outcome, statistically significant superiority
of ameroid constrictor over thin film band was observed (P = .003). No other compar-
isons were statistically significant.
Conclusions and Clinical Importance: The evidence base of choice of treatment of
cEHPSS in dogs remains weak despite recent publications on the subject. Ameroid is
superior to thin film band in causing EHPSS closure. Blinded randomized studies compar-
ing different treatment modalities, which routinely include postoperative imaging to
assess cEHPSS closure and acquired portosystemic shunt development are essential.
Abbreviations: APSS, acquired portosystemic shunts; cEHPSS, congenital extrahepatic portosystemic shunt; CI, confidence interval; CTA, computer tomography angiography; I2, heterogeneity;
IHPSS, intrahepatic portosystemic shunt; MRA, magnetic resonance angiography; NMA, network meta-analysis; NME, network meta-analysis estimates; PAS-OD, polyacrylic acid-silicone gradual
occlusion device.
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1 | INTRODUCTION
The first study reporting congenital extrahepatic portosystemic shunt
(cEHPSS) management in dogs was published in 1976 and since that
time, several medical and surgical or interventional approaches have
been suggested and applied.1-6 Although surgical or interventional treat-
ment is recommended over medical management,7 not all patients are
ideal surgical or interventional candidates. Treatment options might be
influenced by the owner's financial capacity, patient's clinical signs and
concomitant diseases, anesthetic risk, and shunt morphology.8 In the
past, complete ligationwas the treatment of choice in dogs that tolerated
complete cEHPSS occlusion intraoperatively, with maximum attenuation
of a cEHPSS in a single procedure based on portal pressure measured
during the procedure and subjective visual criteria during shunt occlu-
sion.9,10 In recent years, gradual occlusion methods (thin film band,
ameroid constrictor, and coil embolization) have become popular in
an attempt to minimize the risk of perioperative complications, life-
threatening portal hypertension, and to treat the high percentage of dogs
that do not tolerate acute shunt occlusion.2,4,9 In order to elect the best
treatment modality for cEHPSS, comparison of the different available
techniques and their overall outcome is needed. In 2012, an evidence-
based review based on English language peer-reviewed papers assessed
the quality of evidence.6 Our study differs from the previous study
because we applied an intensive search without date (until 2018) or lan-
guage restrictions, employed the use of 95% confidence intervals (CI) in
data assessment, and performed a networkmeta-analysis (NMA) to com-
pare different techniques. Our goal was to provide an updated and
extended evaluation, comparing current published evidence on the dif-
ferent treatment options for dogs with cEHPSS based on objective
criteria, in order to provide small animal clinicians with evidence-based
information about the available treatment modalities and associated
short- and long-term outcomes. To do so, we used a PICO framework to
develop the literature search strategy. The PICO acronym stands for: P,
patient, problem, or population; I, intervention; C, comparison, control,
or comparator; and O, outcome. Hence, our PICO question was “What is
the best treatment technique in the short and long-term for the treat-
ment of cEHPSS in dogs?”
2 | MATERIALS AND METHODS
2.1 | Search strategy
The literature search aimed to identify all studies evaluating the clini-
cal effectiveness of medical, surgical, or interventional treatment
of cEHPSS in dogs. Article selection and data extraction were per-
formed by the primary author (G.S.) and assisted by the coauthors
(N.D. and F.M.). When conflicts existed, studies were evaluated based
on the inclusion criteria below:
• Criterion 1: Type of study: peer-reviewed studies and congress
abstracts. Clinical trials and case series were included if these
described >5 dogs.
• Criterion 2: Case diagnosis: dogs with cEHPSS, either with or without
clinical signs related to the cEHPSS, were included. Confirmation of
the cEHPSS by portovenography, computed tomography angiogra-
phy (CTA), portal scintigraphy, abdominal ultrasonography, magnetic
resonance angiography (MRA), or identification of the shunt vessel
during surgery was essential. Dogs were excluded if the type of shunt
(extrahepatic versus intrahepatic) was not defined. Dogs with a diag-
nosis of up to 2 cEHPSSwere included.
• Criterion 3: Treatment: dogs managed by medical treatment, surgi-
cal, or interventional or both were included. Medical treatment
consisted of dietary treatment, lactulose, antibiotic treatment, or
some combination of them. For dogs that underwent surgical or
interventional treatment, only the outcomes and follow-up from
the first intervention were considered. The type of surgery had to
be clearly documented.
• Criterion 4: Outcome: studies had to include (or provide enough
information to deduce) perioperative outcome and long-term clinical,
surgical, or interventional follow-up, with description of general
patient condition and survival time. Improvement or worsening of the
patient's general condition, assessed by a clinician or the owner, had
to be reported. Studies selectively reporting on cEHPSS complica-
tions or management of these complications were excluded. Studies
in which outcomes for multiple surgical or interventional treatments
(eg, ameroid constrictor and ligation) could not be differentiated were
excluded. Studies describing cEHPSS and intrahepatic portosystemic
shunts (IHPSS) together were excluded if the different shunt types
(cEHPSS versus IHPSS) could not be distinguished with regard to
outcome, except for studies in which the IHPSS cases did not exceed
5%of the total population.
Electronic search engines for publication databases, reference lists
of published papers, and proceedings of relevant scientific confer-
ences were used to search all possible pertinent papers. The utilized
databases were PubMed (www.ncbi.nlm.nih.gov/PubMed) and Web
of Science (www.webofknowledge.com). Electronic searches were
undertaken until October 20, 2018, by the primary author (G.S.) and
2 of the coauthors (N.D. and F.M.) independently without date or lan-
guage restriction. Details of the search strategy are presented in
Supporting Information S1. Articles searched from reference lists of
publications and proceedings from 1990 to 2018 (or the first meeting
after 1990) of major internal medicine and surgery conference meet-
ings (European College of Veterinary Internal Medicine - Companion
1866 SERRANO ET AL.
Animals Congress, American College of Veterinary Internal Medicine
Forum, European College of Veterinary Surgery Annual Scientific
Meeting, and American College of Veterinary Surgery Veterinary Sym-
posium). Other proceedings were included if manual search or elec-
tronic search identified pertinent information. All results returned
from electronic, manual, and reference list searches were recorded
and analyzed.
2.2 | Study selection
Studies written in languages other than English were assessed by a
veterinarian fluent in the language of publication (Portuguese, Greek,
Dutch, German, French, and Spanish). A 2-stage screening process
was used by the primary author (G.S.).11 All studies that fulfilled crite-
rion 1 and reported findings on cEHPSS in dogs were analyzed based
on title and abstract. Stage 2 identified papers that fulfilled criteria
2, 3, and 4. These were evaluated in detail for the type of paper, diag-
nostic methods used, treatment method, perioperative outcome, clini-
cal outcome, surgical or interventional outcome, and follow-up time
(see below for definitions).
2.3 | Assessment of quality of evidence
For every study selected, a modified Preferred Reporting Items for Sys-
tematic reviews and Meta-Analyses classification was performed similar
to a previous study.11 Studies were assessed for the level of evidence
based on amodified “Oxford Centre for Evidence-BasedMedicine” grad-
ing system. The grading system was modified to remove categories that
were not applicable to the present study. Furthermore, “grade 4” evi-
dence was subdivided in to 3 subgroups to allow greater differentiation
among the evidence available, similar to a previous publication6 (Table 1).
A fusion of original “grade 4c” and “grade 4d” subgroups was performed,
becoming simply “grade 4c,” as both refer to case series from which the
treatment technique can be identified and outcome assessed. Abstracts
were included in “grade 5.” A 3-part system of evidence quality assess-
ment consisting of study group size, subject enrollment quality, and over-
all risk of bias was used to characterize the strengths and weaknesses of
each study.11
2.4 | Study group sizes
Depending on the number of subjects per group, each study was cate-
gorized using the following system: (1) large: >50 subjects per group;
(2) moderate: 20-50 subjects per group; (3) small: 10-19 subjects per
group; and (4) very small: <10 subjects per group.11
2.5 | Subject enrollment quality
Studies were classified as “clearly characterized” (ie, cEHPSS diagnosis
was based on imaging techniques or on cEHPSS identification during sur-
gery with available outcomes for the cEHPSS) or as “mixed characteriza-
tion” (ie, the study had clear characterization of the cEHPSS, but
reported combined outcomes for dogs with IHPSS and cEHPSS). If the
IHPSS population was >5% of each particular outcome, that outcome
was not evaluated. Additionally, each study was evaluated for type of
shuntmorphology (ie, portocaval, portoazygos, and portophrenic).
2.6 | Overall risk of bias assessment
The overall risk of bias for the studies was evaluated based on the
Cochrane “risk of bias” tool.12 Each of the following components was
categorized as having a “low,” “moderate,” “high,” or “unclear” risk of
bias: random sequence generation, allocation concealment, blinding of
participants, personnel and outcome assessment, incomplete data,
selective reporting, and other sources of bias. Subsequently, the over-
all risk of bias for each article was determined (categorized as “low,”
“low to moderate,” “moderate,” “moderate to high,” or “high.” For
group 4 studies, the overall risk of bias assessment was not applicable
and they were categorized as studies with an overall “high” risk
of bias.
2.7 | Assessment of outcome measures
2.7.1 | Classification
For each report included in this review, the medical management, surgi-
cal, or interventional technique or both was identified and statistically
assessed (survival, clinical, and surgical or interventional outcome per-
centages; 95% CI and forest plots) by the main author (G.S.) and
TABLE 1 Levels of evidence
Grade Description
1a Systematic review with homogeneity of RCT
1b Individual RCT (with narrow confidence interval)
2a Systematic review (with homogeneity) of cohort studiesa
2b Individual cohort studies (including RCT)
3a Systematic review (with homogeneity) of case-control
studiesb
3b Individual case-control study
4a Lower quality prospective cohort/case-control study—
concerns regarding definition of comparison groups
and/or objective (preferably blinded) nature of
assessment and/or consideration of confounding
factors and/or adequacy of follow-up
4b Retrospective cohort/case-control studies
4c Case series
5 Expert opinion without explicit critical appraisal, or based
on physiology, bench research or “first principles”
Notes: Adapted from Oxford Centre for Evidence Based Medicine and
Tivers et al.6 “Grade 4” of evidence was subdivided in 3 subgroups in
order to allow greater differentiation among the evidence available.
Abbreviation: RCT, randomized clinical trial.
aA cohort study is a study that follows a group of patients over a period of
time and investigates the effect of a treatment or risk factor.
bA case-control study is 1 that examines the effect of a risk factor on the
outcome for a group of patients with a disease compared to that of a
matched control group without the disease.
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1 coauthor (N.D.) working independently. When disagreement occurred,
the other coauthors (M.C., H.R., and F.M.) were consulted to resolve the
controversy. The term “thin film band” will be used throughout this
review when referring to cellophane, to materials alleged to be cello-
phane, or to other thin films. The term “ligation”was applied to both par-
tial ligation and complete ligation throughout this review. Studies were
assessed based on:
1. “Perioperative outcome” (ie, characterized by survival from the
moment of anesthetic induction until 1 week after surgery).
2. “Clinical outcome” (ie, characterized by presence, persistence, or
severity of postoperative clinical signs as assessed either by a clini-
cian or by the owner at final follow-up).
3. “Surgical or interventional outcome” (ie, characterized by closure
state of the cEHPSS and the development of acquired portosystemic
shunts [APSS] as assessed by portovenography, CTA, portal scintig-
raphy, abdominal ultrasonography,MRA, or revision surgery).
For studies in which survival and outcomes of individual dogs
could not be deduced, median or mean survival times were used. If
solely medical management was chosen, only clinical outcome at
follow-up or median or mean survival times were assessed. “Medical
clinical outcome” was defined as presence, persistence, or severity of
clinical signs as assessed either by a clinician or by the owner at final
follow-up time.
A classification system was developed to report clinical (C0-3) and
surgical or interventional (S0-2) outcomes of the different techniques
(Table 2):
In patients categorized as S1, surgery was successful in closing the
cEHPSS without concomitant development of APSS; patients catego-
rized as S2 were considered a surgical or interventional failure, inde-
pendently of the C status. Patients categorized as C1 or C2 were
considered clinical successes whereas patients categorized as C3 were
considered clinical failures, independently of S status. In a patient cat-
egorized as C3S1 (clinical failure despite surgical or interventional suc-
cess), it cannot be excluded that the clinical abnormalities were
secondary to other concomitant pathologies, unrelated to cEHPSS
disease.
Medically treated dogswere only assessed based on C classification.
When solely “outcome” is mentioned, it relates to the combined
subjective analysis of all 3 outcomes (perioperative, clinical, and surgi-
cal or interventional).
2.7.2 | Prevalence and 95% CI of outcome success
The perioperative, clinical, and surgical or interventional outcomes
were calculated by dividing the number of successful cases in each
study by the total number of cases reported in that study. The 95%
CI, using Wilson score interval, was calculated for each of the 3 mea-
sured success variables assessed.13 For each of the studies included,
the follow-up time was reported so as to make the assessment more
objective.
2.7.3 | Statistical analysis
To compare different techniques, a NMA was performed.14 This
methodology (NMA) was chosen over a simple direct comparison
among techniques. For example: a study comparing techniques A
and B, showing technique A as 2 times more efficacious than B, and
another study comparing techniques A and C, showing A as 4 times
more efficacious than C. By indirect comparison, one could conclude
that treatment B is twice as effective as C. The use of this approach
can induce error by failing to incorporate uncertainty about the
within-trial direct estimates (eg, the samples size in each comparison
group) and use of the NMA model has the advantage of allowing com-
parison among techniques in a single analysis, using either direct or
TABLE 2 Classification system developed to report on clinical (C0-C3) and surgical or interventional (S0-S2) outcome of the different
techniques
S0 S1 S2
C0 NA No clinically information reported
Closed cEHPSS and no APSS present at imaging
technique
No clinically information reported
Patent cEHPSS and/or presence of APSS at
imaging technique
C1 Clinically normal dog receiving no medical
treatment
No surgical/interventional information reported
Clinically normal dog receiving no medical
treatment
Closed cEHPSS and no APSS present at imaging
technique
Clinically normal dog receiving no medical
treatment
Patent cEHPSS and/or presence of APSS at
imaging technique
C2 Clinically normal dog or minimal clinical signs
(eg, occasional lethargy or diarrhea) on
medical treatment
No surgical/interventional information reported
Clinically normal dog or minimal clinical signs
(eg, occasional lethargy or diarrhea) on
medical treatment
Closed cEHPSS and no APSS present at imaging
technique
Clinically normal dog or minimal clinical signs
on medical treatment for cEHPSS
Patent cEHPSS and/or presence of APSS at
imaging technique
C3 Clinically abnormal dog with clinical signs
compatible with a cEHPSS
No surgical/interventional information reported
Clinically abnormal dog with clinical signs
compatible with a cEHPSS
Closed cEHPSS and no APSS present at imaging
technique
Clinically abnormal dog with clinical signs
compatible with a cEHPSS
Patent cEHPSS and/or presence of APSS at
imaging technique
Note: “Bold” signifies the meaning of the “C” classification, and “italic” signifies the meaning of “S” classification.
1868 SERRANO ET AL.
indirect evidence while accounting for lack of randomization at study
level. Direct evidence is defined as evidence obtained directly from
studies comparing at least 2 treatment modalities, (eg, techniques A
and B). Indirect evidence is obtained using ≥1 common comparators
(eg, in the absence of studies comparing techniques A and B, tech-
niques A and B can be compared indirectly if both have been com-
pared with treatment C). Mixed evidence is defined as the
combination of direct and indirect evidence.15,16
An NMA comparing perioperative, clinical, and surgical or inter-
ventional outcome for different techniques was performed. Network
graphs were provided for visualization of the geometry of the net-
work. A league table was generated to present the results of both
direct estimate comparisons and network meta-analysis estimates
(NME) and a forest plot was generated to compare the assessed treat-
ment modalities to ameroid constrictor.14 A treatment ranking for
each outcome was provided based on P-score. All NMA analyses were
performed in R-package “netmeta” using frequentist methods (version
0.9-8).17 The odds ratio (OR), using the random effects model, was
estimated to indicate higher or lower odds for successful outcome in
1 group of dogs compared to a relevant comparison group. The ran-
dom effects model was selected because it assumes that the observed
estimates of treatment effect may vary across studies because of
actual differences in treatment effect and sample heterogeneity in
each study. When τ2 is estimated to be zero in the pairwise treatment
comparisons, the model is reduced to the fixed effects model. Hetero-
geneity among studies was calculated using the Chi-square test and
was considered significant when P ≤ .1. The fraction of variance
because of heterogeneity (I2 value) was assessed using GRADE guide-
lines with “no more than 40%,” “30 to 60%,” “50 to 90%,” and “75 to
100%” considered as “low,” “moderate,” “substantial,” and “consider-
able” heterogeneity, respectively. The term τ2 is the variance of the
effect size parameters across the study population and indicates the
variance of the true effects size. The τ2 value was reported between
0 and 1, with T2 close to 0 indicating no heterogeneity. Inconsistency
of the network was assessed by comparing direct and indirect esti-
mates. P-score was used for ranking the different techniques, with
higher P-score meaning a better treatment effect. When network
assessment was not possible for an outcome (perioperative, clinical
and surgical or interventional), direct meta-analysis outcomes were
compared among different surgical or interventional techniques and
among different cEHPSS morphologies treated using the same tech-
nique. For this, a similar approach, as in previous meta-analyses,
was conducted to identify statistical differences among studies that
included comparable cases regarding outcomes.11 Review Manager
5.3 software was used for the dichotomous comparisons.
3 | RESULTS
3.1 | Assessment of quality of evidence
By October 20, 2018, the search strategy identified 645 unique cita-
tions, 631 from the electronic searches of PubMed and Web of Sci-
ence and manual searches from the publication's reference lists and
14 from manual searching of major conference proceedings. Two-
hundred twenty-four papers fulfilled stage 1 screening criteria, of
which 48 (published between 1979 and 2018) also fulfilled stage
2 selection criteria and were selected for review (Figure 1). Based on
grading of the level of evidence, 6 studies were included in subgroup
4b,18-23 35 in subgroup 4c,2-5,24-54 and 7 in grade 5.55-61
Overall, the 48 selected papers reported 6 different surgical or
interventional techniques and several different medical treatments.
Within each paper, ≥1 treatment techniques were evaluated. In 8 stud-
ies reporting “ligation,” where it was possible to distinguish between
cases that had complete or partial ligation,21,23,26,32,40,42,47,54 statisti-
cal analysis was performed to compare outcome between the 2 liga-
tion techniques.
3.2 | Study groups size
A combined total of 1417 dogs affected by cEHPSS were reported in the
48 studies. Eleven studies evaluated very small numbers of dogs (<10
dogs).3,5,18,24,29,35,53,55,58,61,62 Fourteen studies evaluated small numbers of
dogs (10-19 dogs).2,4,20,26,28,31,34,39-41,44,47,56,57 Fifteen studies evaluated
moderate numbers of dogs (20-50 dogs).19,22,23,27,30,32,41,42,45,46,50-52,54,59
Eight studies evaluated large numbers of dogs (>50 dogs).21,36-38,48,49,60,63
3.3 | Subject enrollment quality
Forty-six studies were clearly characterized (including 100% cEHPSS),
with 2 studies being of mixed characterization (≤5% IHPSS).27,57 Con-
genital extrahepatic portosystemic shunts were described with regard
to their termination in 1001 dogs, caudal vena cava (n = 747), azygos
vein (n = 232), or phrenic vein (n = 26).
3.4 | Overall risk of bias
Most of the trials had high or unclear risk of bias for all components.
In 15 studies,3,18,19,21,23,26,28,32,37,38,41,45,49,54,63 the number of initially
enrolled dogs was higher than the final number of dogs with reported
survival or outcomes. Reasons for incomplete follow-up included fail-
ure to contact the owners after surgery or lack of postsurgical or
interventional evaluations, euthanasia, or other unidentified reasons.
Seven studies were congress abstracts.55-61
3.5 | Individual assessment of different treatment
options
3.5.1 | Medical management (Supporting
Information S2)
Three studies evaluated the efficacy of medical management for
cEHPSS, giving a combined sample of 13 dogs,3,28,34 with a median
follow-up time of 2.3 to 57.5 months. Medical management consisted
of a combination of therapeutic diet, antibiotics, and lactulose. All
3 components varied among studies and even within the same study.
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3.5.2 | Ligation (Supporting Information S3)
Twenty-five studies21-32,34,36,38-40,42,43,46,47,54,58,61-63 evaluated the effi-
cacy of ligation as treatment for cEHPSS, giving a total number of
553 dogs. Perioperative outcome was reported in all studies except
230,31 and was available in 514 of the 553 dogs, with 463 surviving the
perioperative period (90.1%). Clinical outcomewas described in 19 stud-
ies.21,23,26-32,34,38-40,43,46,47,54,58,61 From the initial 553 dogs, information
about clinical outcome was available in 342 dogs with clinical outcome
being successful in 255 dogs (74.6%; C1, C2). Median follow-up time var-
ied between 1 and 27.5 months. Surgical or interventional outcome was
available in 5 studies.29,30,39,40,47 Information about surgical or interven-
tional outcome was available in 58 dogs with surgical or interventional
outcome being successful in 38 dogs (65.5%; S1).
In 1321-23,26,30-32,34,40,42,47,54,59of the 25 studies that described
ligation of the cEHPSS, it was possible to evaluate partial ligation as
surgical or interventional treatment in 186 dogs. Perioperative out-
come could be determined in all studies except 5,30-32,34,47 and was
described in 113 of the 186 dogs with 99 dogs having successful out-
come (87.6%). Clinical outcome was available for all studies except
222,42 and was described in 122 of 186 dogs, with clinical outcome
being successful in 99 dogs (81.1%; C1, C2). Median follow-up time
varied between 1 and 50.4 months. Surgical or interventional
outcome was available in 3 studies30,40,47 and described 29 dogs with
17 having successful outcome (58.6%; S1).
In 1121-23,26,31,32,34,40,42,47,54 of the 25 studies that described liga-
tion of the cEHPSS, it was possible to evaluate complete ligation as sur-
gical or interventional treatment in 75 dogs. Perioperative outcome
could be determined in all studies except 4,31,32,34,47 and was described
in 47 of 75 dogs, with 43 dogs having successful outcome (91.5%).
Clinical outcome was available for all studies except 222,42 and was
described in 52 of 75 dogs, with clinical outcome being successful in
50 dogs (96.1%; C1, C2). Median follow-up time varied between 1 and
54 months. Surgical or interventional outcome was available in 2 stud-
ies40,47 and was available in only 7 dogs with all 7 having successful
outcome (100%; S1).
3.5.3 | Ameroid constrictor (Supporting
Information S4)
Thirteen studies4,18-23,48-50,57,58,60 evaluated ameroid constrictor as
treatment for cEHPSS, giving a total number of 507 dogs. Perioperative
outcome was reported in all studies. From the initial 507 dogs that
underwent the procedure, 479 dogs survived the perioperative phase
















































F IGURE 1 Flow diagram for
inclusion of studies in the
combined systematic review and
meta-analysis. Source: Moher D,
Liberati A, Tetzlaff J, Altman DG,
The PRISMA Group. Preferred
reporting items for systematic
reviews and meta-analyses: the
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described 203 dogs with 192 dogs having successful outcome (94.6%;
C1, C2). Median follow-up time varied between 9 and 54 months. Surgi-
cal or interventional outcome was available in 5 studies4,18,19,23,50 and
described 61 dogswith 50 dogs having successful outcome (82.0%).
3.5.4 | Thin film banding (Supporting Information S5)
Eleven studies2,18-20,37,41,44,45,51,52,55 evaluated thin film banding as
surgical or interventional attenuation for cEHPSS giving a total num-
ber of 269 dogs. Perioperative outcome was reported in all studies.
From the initial 269 dogs that underwent the procedure, 260 dogs
survived the perioperative period (96.7%). Clinical outcome was avail-
able in 6 studies2,19,20,37,41,44 and described in 139 dogs, with success-
ful outcome in 136 (97.8%; C1, C2). Median follow-up time varied
between 2 and 36 months. Surgical or interventional outcome was
available in 7 studies2,18,19,44,51,52,55 and described 90 dogs with
51 dogs having successful outcome (56.7%).
3.5.5 | Coil embolization (Supporting Information S6)
Four studies35,56,59,60 evaluated coil embolization as treatment for sin-
gle cEHPSS, giving a total number of 63 dogs. Perioperative outcome
was reported in all studies. From the initial 63 dogs that underwent
the procedure, 52 dogs survived the perioperative period (82.5%).
Clinical outcome was available for 2 studies35,59 and described 24 dogs
with all having successful outcome (100%; C1, C2). Median follow-up
time varied between 3 and 12 months. Surgical or interventional out-
come was available in 2 studies56,59 and described in 29 dogs with
22 dogs having successful outcome (75.9%).
F IGURE 2 A, Network graph of the perioperative outcome; B,
perioperative outcome with ligation divided in complete and partial
ligation; and C, clinical outcome with ligation divided in complete and
partial ligation. The nodes in the graph represent the different
treatments. The line between treatment shows that there is at least
1 study comparing these 2 treatments. The thickness of the line is
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3.5.6 | Amplatzer vascular plug (Supporting
Information S7)
One study5 evaluated the efficacy of the Amplatzer vascular plug as
treatment for single cEHPSS in 6 dogs. From the initial 6 dogs in
which the Amplatzer occlusion was possible, all survived the perioper-
ative period (100%). Clinical outcome was available for the 6 dogs and
was successful in all 6 (100%). All dogs were followed for at least
1 month. Surgical or interventional outcome could not be assessed,
because no postoperative imaging was performed in any of the dogs.
3.5.7 | Polyacrylic acid-silicone gradual occlusion
device (Supporting Information S8)
One study53 evaluated the efficacy of a polyacrylic acid-silicone grad-
ual occlusion device (PAS-OD) as treatment for single cEHPSS in
6 dogs. All 6 dogs survived the perioperative period (100%). Clinical
outcome was available for the 6 dogs and was successful in all
6 (100%; C1, C2). All dogs were followed for 2 months. Surgical or
interventional outcome was available in all 6 dogs with 4 dogs having
successful outcome.
3.6 | Meta-analysis
3.6.1 | Perioperative outcome
Ligation versus ameroid constrictor versus thin film band
An NMA for the perioperative outcome variable was performed to com-
pare multiple treatments: ligation, ameroid constrictor, and thin film
band. Adequatedata to calculateOR for theNMAwas available in 4 stud-
ies.19-22 A graph of the network perioperative outcome was generated
(Figure 2). A league table was generated to present the results of both
direct comparisons andNME (Table 3). Ameroid-ligationNMEwas based
on 100% direct evidence. Ligation-thin film band NME was 100% based
on indirect evidence. No statistically significant differences were found
in any treatment comparison by either direct or indirect comparison. A
forest plot comparing ameroid constrictor with the remaining techniques
is presented in Figure 3. No statistical difference in perioperative out-
come was found among dogs treated by thin film banding, ameroid con-
strictor placement, or ligation (Table 4). No heterogeneity or network
inconsistencywas observed (T2 = 0; I2 = 0%).
Partial ligation versus complete ligation versus ameroid constrictor
versus thin film band
An NMA for the perioperative outcome variable was performed to
compare multiple treatments: partial and complete ligation, ameroid
constrictor, and thin film band. Adequate data to calculate OR for the
NMA was provided by 6 studies.19-22,26,40 A graph of the network
perioperative outcome was generated (Figure 2). A league table was
generated to present the results of both direct comparisons and NME
(Table 3). Direct and indirect comparisons of outcomes were similar
for all treatment comparisons, except for the comparison between
ameroid constrictor and complete ligation. In the comparison ameroid
constrictor-complete ligation, the proportion of direct evidence
contributing to the NME was 69%. The remaining 31% came from
indirect evidence. Direct comparison between the 2 techniques iden-
tified increased odds for success in the complete ligation group, but
indirect comparison indicated increased odds for success in the amer-
oid constrictor group. For the comparison between complete ligation-
thin film band and partial ligation-thin film band, no direct evidence
was available (no papers compared both techniques) and the NME
were based on indirect evidence. Direct comparisons accounted for
95.3% of the ameroid constrictor-partial ligation comparison, 99.2%
of complete-partial ligation and 100% of ameroid constrictor-thin film
band. No statistically significant differences were found in any treat-
ment by either direct or indirect comparison. Because of overlap
between CIs, no statistical superiority of 1 treatment over another
could be determined. A forest plot comparing ameroid constrictor
with the remaining techniques is presented in Figure 4.
F IGURE 3 Forest plot comparing perioperative outcome of
ligation and thin film band in regard to ameroid constrictor. No
statistically significant differences were noted. CI, confidence interval;
OR, odds ratio
TABLE 4 Treatment ranking regarding comparison of perioperative and clinical outcome among treatments
Perioperative outcome
Perioperative outcome (with ligation divided
in partial and complete)
Clinical outcome (with ligation divided
in partial and complete)
Ranking Technique P-score Ranking Technique P-score Ranking Technique P-score
1 Thin film band .80 1 Thin film band .82 1 Complete ligation .81
2 Ameroid .47 2 Ameroid .58 2 Ameroid .52
3 Ligation .23 3 Partial ligation .38 3 Partial ligation .17
4 Complete ligation .23
Notes: Bigger P-scores indicate a better treatment effect. Rankings near 1 suggest better treatment effect. No statistically significant differences were
noted.
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No significant difference was found among perioperative out-
comes in dogs treated by thin film banding, ameroid constrictor place-
ment, or partial or complete ligation (Table 4). No heterogeneity or
network inconsistency was observed (T2 = 0; I2 = 0%).
3.6.2 | Clinical outcome
Complete ligation versus partial ligation versus ameroid constrictor
An NMA for the clinical outcome variable was performed to compare
multiple treatments: complete ligation, partial ligation, and ameroid
constrictor. Adequate data to calculate OR for the NMA was provided
by 3 studies.21,23,32 A graph of the network clinical outcome was gen-
erated (Figure 2). A league table was generated to present the results
of both direct comparisons and NME (Table 3). Direct and indirect
comparisons of outcomes were similar to all treatment comparisons
except for ameroid constrictor-complete ligation. In the ameroid
constrictor-complete ligation comparison, the proportion of direct evi-
dence contributing to the NME was 72%. The remaining 28% came
from indirect evidence. Direct comparison between the 2 techniques
identified increased odds for successful treatment in the ameroid con-
strictor group, but indirect comparison identified increased odds for
successful treatment in the complete ligation group. Direct compari-
sons accounted for 90.9% of the ameroid constrictor-partial ligation
comparison and 98.9% of the complete-partial ligation comparison.
No statistical significant differences were found in any treatment
comparison by either direct or indirect comparison. A forest plot com-
paring ameroid constrictor with the remaining techniques is presented
in Figure 5. Because of overlap between CIs, no statistical superiority
of 1 treatment over another could be identified.
No significant difference was found in clinical outcome among
dogs treated by thin film banding, ameroid constrictor placement, or
partial ligation (Table 4). Low heterogeneity and network inconsis-
tency was observed (T2 = 0.3012; I2 = 12.7%).
Ameroid constrictor versus ligation
Adequate information to calculate OR for clinical outcome comparing
placement of an ameroid constrictor by ligation (complete or partial) was
provided in 2 studies.21,23 The joint estimated OR was 1.37 (95% CI,
0.05-37.93), favoring the ameroid constrictor technique, but this finding
was not statistically significant (P = .85). Moderate heterogeneity was
shown between studies (Chi-square = 2.66, P = .10, I2 = 62%; Figure 6).
3.6.3 | Surgical outcome
Partial versus complete ligation
Adequate information to calculate OR for surgical or interventional
outcome was provided in 2 studies.40,47 The joint estimated OR was
0.37 (95% CI, 0.04-3.82), favoring the complete ligation technique
(P = .41), but this finding was not statistically significant. Low hetero-
geneity was shown between studies (Chi-square = 0.07, P = .79,
I2 = 0%; Figure 7).
Ameroid constrictor versus thin film banding
Adequate information to calculate OR for surgical or interventional
outcome was provided in 2 studies.18,19 The common estimated OR
was 36.58 (95% CI, 3.29-407.10), showing a statistically significant
association (P = .003) between the 2 techniques, with increased odds
of success using the ameroid technique. Low heterogeneity was
shown between studies (Chi-square = 0.03, P = .86, I2 = 0%; Figure 8).
Insufficient data were available to directly compare other treat-
ment modalities.
F IGURE 4 Forest plot comparing perioperative outcome of
complete ligation, partial ligation and thin film band in regard to
ameroid constrictor. No statistically significant differences were
noted. CI, confidence interval; OR, Odds ratio
F IGURE 5 Forest plot comparing clinical outcome of complete
ligation, partial ligation and thin film band in regard to ameroid
constrictor. No statistically significant differences were noted. CI,
confidence interval; OR, Odds ratio
F IGURE 6 Forest plot comparing clinical outcome in ameroid constrictor versus ligation. Odds ratio (95% confidence interval [CI]) of clinical
success between the 2 techniques. No statistically significant differences were noted
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Assessment of surgical technique for cEHPSS morphology
The small number of cases, different follow-up times, and absence of
imaging techniques confirming cEHPSS closure made outcome assess-
ment unreliable and therefore it was not reported.
4 | DISCUSSION
To our knowledge, this study is the first to systematically review and pro-
vide meta-analysis for the treatment of cEHPSS in dogs. An evidence-
based review was published in 2012, and found weak evidence for
the treatment of extrahepatic portosystemic shunts.6 Although 7 years
separate the manuscripts and more papers could be included, the major
conclusion remains, mainly the low-quality evidence of the papers.
However, information gained by this meta-analysis may help veterinary
clinicians when designing and communicating a treatment plan for dogs
with cEHPSS. This combined systematic review and NMA differs from
the previously published report by including studies in which >95% of
the cases included were cEHPSS and adding 22 studies not previously
included,18-20,24,25,29,35,36,43,48-53,55-61 including 2 non-English language
publications.20,25 Inevitably, the quality of the systematic review, and
thus the accuracy of the evidence-based information to be gained, is
strongly influenced by the amount, quality and content of the included
papers. To assess the treatment of cEHPSS, 48 studies were identified
including 1417 dogs with cEHPSS. However, most studies were case
series and thus provided weak evidence. During data retrieval, on only a
single occasion was a different classification of “successful” versus
“unsuccessful” surgical outcome given by the authors. This difference
occurred in a paper assessing 2 different imaging techniques to assess
shunt closure, which have different sensitivities.52 After discussion, a
consensus was obtained. Otherwise, no difference in patient
classification occurred between authors. The comparisons between
techniques (meta-analysis) were based on retrospective studies in 5 of
6 instances. Although inclusion of these retrospective studies could
increase the risk of bias, case series can make a useful contribution in
increasing the evidence base and strengthening the credibility of a
review of an emerging health technology.64 Calculation of heterogeneity
(I2) provides an estimate of the proportion of variability in ameta-analysis
that is because of the differences among included trials, rather by sam-
pling error. Our comparisons included a small number of trials, which can
make calculation of I2 unreliable in our meta-analysis.65,66 Also, wide var-
iation in follow-up times was observed within and among studies and, in
many reports, clinical outcome was based solely upon the owners' sub-
jective evaluation of their dogs' condition after treatment without using
standardized questionnaires or quality-of-life scoring systems. The
development and use of such standardized quality-of-life questionnaires
therefore is recommended.67 Also, publication bias can be a limitation of
this systematic review and NMA, with the possibility of nonpublication
of negative results not being excluded. Studies designed to report com-
plications after surgery were not included in an attempt to decrease this
publication bias, because these studies report only specific clinical signs
and fail to report all complications (eg, reporting postsurgery neurologic
complications while failing to report gastrointestinal or urinary signs).
Abstracts of specialist conferences were included in the systematic
review but not in the meta-analysis. These publications can add impor-
tant information about cEHPSS treatment, but because these manu-
scripts are not peer-reviewed, might consist of low-quality evidence and
might have high bias, data interpretationmust be done carefully. Statisti-
cal comparison and individual study assessment among treatment tech-
niques were performed, based on perioperative outcome (survival in the
perioperative period up to 7 days after the procedure), clinical outcome
(quality of life), and surgical or interventional outcome (closure of the
F IGURE 7 Forest plot comparing surgical outcome in partial versus complete ligation. Odds ratio (95% confidence interval [CI]) of surgical
success between the 2 techniques. No statistically significant differences were noted
F IGURE 8 Forest plot comparing surgical outcome in ameroid constrictor versus thin film band. Odds ratio (95% confidence interval [CI]) of
surgical success between the 2 techniques. The common estimated OR was 36.58 (95% CI, 3.29-407.10), showing a statistically significant
association (P = .003) between the 2 techniques, with increased odds of successful cases in the ameroid technique
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original cEHPSS without development of APSS). Percentage of success-
ful cases was used as an indicator of perioperative, clinical, and surgical
or interventional outcome. The addition of the 95% CI allowed us to bal-
ance the percentage of success, by taking into account the number of
cases reported in each study.
Theoretically, placement of an ameroid constrictor, thin film banding,
or coils will lead to gradual cEHPSS attenuation.4,68,69 When looking
directly at the results of individual studies, thin film band seemed to be
the technique that provided the best perioperative outcome, closely
followed by ameroid constrictor (Supporting Information S2-S8),
whereas coil embolization led to a less favorable perioperative outcome.
However, the number of cases assessed after coil embolization was
4 and 6 times smaller than that after ameroid constrictor placement and
thin film banding, respectively, rendering comparison less accurate. From
a statistical point of view, no differences were found among techniques
for perioperative outcome, and further studies assessing the periopera-
tive outcomes of different techniques are necessary before 1 technique
should be considered superior to another. Factors other than surgical
technique may influence survival. For example, the choice and dosages
of anesthetics often differed among studies (or were not specified). Like-
wise, more or less intraoperative attenuation can be exertedwhen apply-
ing a thin film band around the shunting vessel.41 Furthermore, surgical
skill and expertise with the technique could have had an impact on
morbidity and mortality, with the possibility that the level of periopera-
tive surveillance and critical care may have varied among institutions,
influencing the management of perioperative morbidities. For these rea-
sons, a random effect model was chosen as a statistical model. Regard-
less of these factors, it is generally believed that gradual reduction of
the shunt diameter rather than acute shunt occlusion allows the liver
to adapt to increased portal blood flow, limiting the risk of acute fatal
portal hypertension.2,4 Nevertheless, it is still possible that ameroid con-
strictors lead to kinking and possibly peracute occlusion of the shunting
vessel.4,70
While looking directly at the results of individual studies, place-
ment of an ameroid constrictor and complete ligation appeared to be
the surgical or interventional techniques with strongest evidence of
giving a good quality of life, followed by thin film banding and coil
embolization (Supporting Information S2-S8). The NMA produced
contradictory results for these 2 techniques with increased odds of
better clinical outcome for ameroid constrictor in the direct estimate
comparison but for complete ligation in the indirect estimate compari-
son (Table 3). From a statistical point of view, no significant differ-
ences among techniques were observed for clinical outcome. This
result could be a consequence of the low number of cases and studies
included. More and larger studies (in terms of cases included) are
needed to address this contradiction. The terms clinical success and
surgical or interventional success should not be used interchangeably.
Dogs with a patent cEHPSS or with APSS, both considered surgical
failures, could have been asymptomatic during the follow-up period
and therefore could have been classified as clinical successes. Also,
postoperative screening for shunt status by means of medical imaging
was not consistently performed in most of the studies. Therefore,
outcome often is judged on clinical success without evaluating surgi-
cal or interventional success.
Shunt ligation was by far the best-documented technique in dogs
with cEHPSS.Not only have large numbers been described, but relatively
long follow-up times also were considered, subjectively suggesting that
this technique might lead to higher chances of successful clinical out-
come (Supporting Information S2-S8), but the quality of evidence was
still weak. However, dogs that underwent cEHPSS attenuation using an
ameroid constrictor appeared to have a better subjective overall 95% CI
for clinical outcome compared to dogs in which shunts were ligated.
Median follow-up periods in dogs that received an ameroid constrictor
were considerably shorter than in dogs that underwent cEHPSS ligation,
which might have overestimated the superiority of ameroid constrictors
over ligation. Thin film banding had 95% CI for outcome equivalent to or
even better than that of ameroid constrictor, but smaller numbers of
caseswere assessed and follow-up timeswere shorter than for the previ-
ously mentioned techniques. Standardization of thin film material is
vital.71 Further studies comparing the clinical outcome of ameroid con-
strictor, ligation, and thin film band techniques are necessary before a
single technique should be considered superior to another. Studies
describing coil embolization reported a small number of dogs with short
follow-up times. Although the results of coil embolization seem promis-
ing, studies of a large cohort of patients are needed to better evaluate
this approach. Amplatzer vascular plug embolization only was reported
in a single case series of 6 dogs and follow-up was not well documented.
The same was true for PAS-OD, with only 6 cases that underwent PAS-
OD placement reported. Further studies including higher numbers of
dogs are needed before proposing definite recommendations about
Amplatzer vascular plug and PAS-OD use.
When looking subjectively at the results of individual studies, com-
plete ligation seemed to result in better clinical outcome than did partial
ligation. The lack of a statistically significant difference in outcome
between complete and partial ligation was surprising because it is widely
assumed that complete cEHPSS occlusion provides the highest likeli-
hood of a good long-term quality of life.72 However, the lack of statistical
significance between complete and partial ligation might be explained by
variations in follow-up times between groups. In 1 study,21 dogs with
complete ligation were followed for a median of 58 months, whereas
dogs that underwent partial ligation were only followed for a median of
18 months. For the sake of this meta-analysis, clinical outcome was
deduced from the data available at 18 months for both ligation groups.
It has been reported that clinical signs related to cEHPSS patency
started to reoccur only after a mean follow-up of 36.2 months
(SD = 21.6 months) after partial shunt ligation.30 Therefore, it can be
hypothesized that if the partial ligation group would have had an equally
long follow-up period (58 months), the differences in clinical success
between the 2 approaches might have been more pronounced. Intra-
operatively, it is common to attempt complete ligation of the cEHPSS,
reserving partial ligation for cases in which complete ligation was
deemed impossible based on observation of splanchnic viscera, systemic
arterial pressure, central venous pressure, mesenteric venous pressure,
interpretation of portovenography after temporary ligation, or a combi-
nation of these.73,74 In some institutions, in cases that tolerate only
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partial ligation, a second surgery is performed some months later to
completely occlude the cEHPSS. Because we included only the results of
the first procedure, we might have underestimated the overall outcome
success of the ligation technique. A multi-phase or 2-step ligation sur-
gery might culminate in complete ligation at the last procedure, but also
might increase perioperative morbidity and financial cost for the owner.
We included only the first surgery that cEHPSS patients underwent,
in order to have the most objective criteria to compare all of the
techniques.
It seems logical that postoperative medical support might posi-
tively influence clinical outcome.48 However, the subgroups of surgi-
cally treated dogs with cEHPSS that would benefit the most remain
unclear. Articles often did not mention if additional medical manage-
ment was provided and, even if it was, treatment often was not stan-
dardized. The most common medical management used currently is
combination treatment, usually with a therapeutic diet, antibiotics,
and lactulose, but it is currently unknown whether all components of
this combination treatment are of added value.
The surgical or interventional outcome in dogs with cEHPSS only can
be assessed if medical imaging is performed during follow-up. Serum bile
acid concentrations were used in some studies as a measure of cEHPSS
closure, but it is not uncommon for dogs with closed cEHPSS and no evi-
dence of APSS to have bile acid concentrations that did not return to
normal months after successful surgery.44,50,51,75,76 For this reason, bile
acid concentrations were not evaluated in our systematic review and
meta-analysis. Different imaging techniques, radiologist experience in
performing and interpreting imaging studies and the attenuation devices
themselves can hamper the classification of surgical or interventional
outcome as successful or unsuccessful. In only one-third of the studies
included in our systematic review and meta-analysis was postoperative
medical imaging routinely performed. Additionally, the medical imaging
technique used to assess cEHPSS patency or APSS development varied
within and among the studies.
Furthermore, the time of imaging postsurgery or intervention was
not standardized, with some dogs having imaging techniques as early
as 2 months after the procedure whereas imaging was delayed up to
7 months in other dogs.51,56,75 Applying thin film banding around the
shunting vessel can cause complete occlusion within 8 weeks,2 but
shunts with larger diameters may take longer to occlude.41 Differ-
ences in timing of imaging can influence the classification of the
cEHPSS as being patent or closed.
Comparison of surgical or interventional outcome between ameroid
constrictor and thin film band indicated a statistically significant superior-
ity of ameroid constrictor in causing shunt occlusion. No statistically sig-
nificant difference between thin film band and ligation was noted. The
subjective assessment of results (Supporting Information S2-S8) of indi-
vidual studies with regard to surgical or interventional outcome for the
different techniques seemed to indicate the superiority of ameroid con-
strictor and ligation techniques over thin film banding. Thin film banding
had a subjectively lower surgical or interventional success percentage
withwide 95%CIwhen comparedwith ligation. However, the total num-
bers of cases on which these observations were based were rather small,
overall resulting in wide 95% CIs. Biochemical assessment of commonly
used thin film bands of different origins showed little to no irritant com-
ponents capable of inducing local inflammation necessary for adequate
shunt closure.77 Surprisingly, the composition of most of the commer-
cially available thin film bands was not truly cellophane.71 These findings
might explain the inconsistent efficacy of thin film banding for cEHPSS
closure.
In 1 of the studies18 in which comparison between ameroid con-
strictor and thin film band was possible, none of the 3 thin film band
cases experienced cEHPSS closure 3 months after surgery. In that
study, all thin film bands were placed in the thoracic cavity to attenu-
ate portoazygos shunts. The authors hypothesized that thin film band
behavior might be inferior in the thorax compared to in the abdo-
men.18 Future randomized prospective studies are needed to compare
surgical outcome after ameroid constrictor with different types of thin
film banding. Coil embolization was performed and evaluated only in a
few of cases, indicating a subjective surgical or interventional success
percentage similar to the above-mentioned techniques and also with
a wide 95% CI (Supporting Information S6).
Studies comparing surgical or interventional versus medical manage-
ment of cEHPSS as a sole treatment of cEHPSS and the effect of differ-
ent protein sources on treatment of congenital portosystemic shunts
have been published,7,78 but they could not be included in the current
systematic review and meta-analysis because they did not meet the
inclusion criteria (not defining if cEHPSS or IHPSS and mixing cEHPSS
and IHPSS outcomes). The few included papers evaluating medical man-
agement reported small numbers of cEHPSS cases with short follow-up
times, resulting in a wide 95% CI (Supporting Information S2). Long-term
clinical outcome after different surgical techniques for management of
congenital portosystemic shunts was clearly superior to outcome after
medical management only.7 This difference could not yet be appreciated
at a median follow-up time of 579 days, but only became evident when
the median follow-up time was 1936 days. The shorter follow-up times
reported inmost of the studies included in the current systematic review
andmeta-analysis were therefore insufficient to identify all cases of clini-
cal relapse. Another important fact to consider when comparing medical
versus surgical treatment is that long-term medical management usually
is reserved for cases in which the owner cannot afford the cost of surgi-
cal or interventional procedures, the anesthetic risk to perform surgery is
considered too high, the shuntmorphology is challenging, or the dog only
showsmild clinical signs.8 These factors probably introduce considerable
bias when it comes to comparison of solelymedically managed cases ver-
sus those that were additionally treated using surgical or interventional
techniques.
A comparison of perioperative, clinical, and surgical or interventional
outcomes for different cEHPSS morphologies (portocaval versus
portoazygos) was attempted. However, an objective recommendation
for or against specific treatment modalities for specific cEHPSSmorphol-
ogies was impossible, because of the small number of cases, variable
follow-up times, and absence of imaging techniques to confirm cEHPSS
closure, APSS development or both. Larger studies, including standard-
ized postoperative imaging techniques, are needed because different
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cEHPSS morphologies might have different responses to treatment
techniques.18
5 | CONCLUSION
No technique was shown to be conclusively superior to any of the
others. Based on our systematic review and meta-analysis, dogs with
cEHPSS will benefit most from placement of an ameroid constrictor over
thin film band to achieve good surgical outcome. The strength of this
conclusion is, however, limited because of the low quality of evidence
given the absence of unbiased, large, randomized, prospective studies
available for dogs with cEHPSS. The general evidence quality is low
because most studies were in grade 4c—case series (35/48), 6 were
grade 4b, and 7 were grade 5. Direct and indirect estimates in some
NMA comparisonswere not consistent and all other comparisons among
treatment modalities identified no significant differences. In order to
make objective and strong evidence-based recommendations for veteri-
nary practitioners, well-designed, large-scale studies comparing different
surgical or interventional andmedical management options for dogs with
cEHPSS are needed. Future studies ideally should include advanced
imaging techniques for unambiguous cEHPSS morphology classification
and for postoperative assessment of cEHPSS patency or APSS develop-
ment. The ideal timing for postsurgical or interventional imaging should
be defined and standardized. Imaging techniques must be compared for
their ability to evaluate cEHPSS closure and detection of APSS, so as to
establish a gold standard postoperative imaging protocol. Finally, future
studies should evaluate clinical outcome on a long-term basis, using stan-
dardized questionnaires or validated quality-of-life scoring systems.67
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